Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2020 Earnings Conference Call - Final Transcript
Feb 10, 2020 • 04:30 pm ET
Good day and welcome to the Aethlon Medical Third Quarter Fiscal 2020 Earnings and Corporate Update. [Operator Instructions] I would now like to turn the conference over to Jim Frakes, Chief Financial Officer. Please go ahead.
James B. Frakes
Thank you, operator, and good afternoon, everyone. Welcome to Aethlon Medical's third quarter 2020 earnings conference call. My name is Jim Frakes, and I'm Aethlon's Chief Financial Officer. At 4:15 pm Eastern Time today, Aethlon Medical released financial results for its third quarter ended December 31, 2019. If you have not seen or received Aethlon Medical's earnings release, please visit the Investors page at www.aethlonmedical.com.
Following this introduction and the reading of our forward-looking statements, Aethlon CEO, Dr. Tim Rodell; and our Chairman, Dr. Chuck Fisher, will provide an overview of Aethlon's strategy and recent developments. I will then make some brief remarks on Aethlon's financials.
We will then open up the call for the Q&A session. Before I hand the call over to Dr. Rodell, please note that the news release today and this call contain forward-looking statements within the meaning of the Federal Securities Act of 1933 and the Securities Exchange Act of 1934. The Company cautions you that any statement that is not a statement of historical fact is a forward-looking statement. These statements are based on expectations and assumptions as of the date of this conference call. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements.
Factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption risk factors in the Company's annual report on Form 10-K, for the fiscal year ended March 31, 2019, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend or does it undertake any duty to update this information to reflect future events or circumstances.With that, I will now turn the call over to Dr. Tim Rodell, Aethlon Medical's CEO.
Timothy C. Rodell
Thank you, Jim, and thank you all for dialing into our earnings call. I'd like first to briefly address the suspension in trading of the Company's shares by the Securities and Exchange Commission on Friday. We will then update on the progress of our programs in oncology, and we'll then discuss our view of the evolving coronavirus outbreak and the potential relevance of the Hemopurifier in this and future viral epidemics. As you know, on February 7, 2020, the Securities and Exchange Commission issued an order of suspension of trading, temporarily suspending trading in Aethlon Medical Incorporated stock for a period of 10 days.
The SEC order stated that the suspension was due to concerns regarding the accuracy and adequacy of information in the marketplace that appeared to be disseminated by third-party promoters and recent and unusual market activity since at least January 22, 2020.
Aethlon is aware of certain third-party promoters that have made claims about